Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2025 09:00 ET | Source: HealthEx

MD Anderson and HealthEx Announce Collaboration to Develop New Platform to Give Patients Direct Control of Data Access

The University of Texas MD Anderson Cancer Center and HealthEx are developing an AI platform to give patients more control in how their data is used.
April 21, 2025 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics,...
November 08, 2024 08:00 ET | Source: Artidis AG

ARTIDIS announces publication demonstrating the nanomechanical signature of response to low-dose radiotherapy followed by CAR T cell therapy in solid tumors.

BASEL, Nov. 8, 2024 — ARTIDIS, a clinical-stage health technology company developing the first clinically integrated nanomechanical platform for tissue analytics, today announced a peer-reviewed...
October 21, 2024 09:00 ET | Source: The American Journal of Managed Care

The Institute for Value-Based Medicine® from The American Journal of Managed Care® hosts “Cardiac Care in a Value-Based World” event in Phoenix

CRANBURY, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- The American Journal of Managed Care® (AJMC®), the leading multimedia peer-reviewed journal dedicated to issues in managed care, is pleased to...
August 22, 2024 12:25 ET | Source: The Joint Commission

Reducing Handoff Communication Failures and Inequities in Healthcare

OAKBROOK TERRACE, Illinois, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Inspiring studies related to two common sources of adverse events in healthcare – handoff communication failures, and bias and...
July 11, 2024 12:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in...
March 21, 2024 07:00 ET | Source: Cancer Focus Fund; Eisbach Bio GmbH

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

Cancer Focus Fund is investing $4.5M for clinical trial of Eisbach's novel approach using synthetic lethality to kill PARP inhibitor resistant tumors
June 20, 2023 07:00 ET | Source: Replay Bio

Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma

Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma First-in-human Phase 1 study of NY-ESO-1...
October 03, 2022 09:05 ET | Source: ARTIDIS AG

MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment

HOUSTON and BASEL, Switzerland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- ARTIDIS AG, the developer of the first nanomechanical technology platform for tissue analytics, and The University of Texas MD...
February 19, 2020 12:00 ET | Source: Houston Dynamo

Houston Dash join Dynamo, MD Anderson in Making Cancer History

HOUSTON, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center today announced the Houston Dash will join the institution's efforts toward one goal: end cancer....

Next Page keyboard_arrow_right